AstraZeneca to contest US court ruling over asthma medicine

Drugmaker AstraZeneca announced Tuesday that a US court ruled that its patent protecting its medicine Pulmicort Respules in the nation is invalid.

Drugmaker AstraZeneca announced Tuesday that a US court ruled that its patent protecting its medicine Pulmicort Respules in the nation is invalid.

The company said it strongly disagreed with the District Court of New Jersey's decision over the drug, which is used for the treatment of asthma.

"AstraZeneca has full confidence in the strength of its intellectual property rights protecting Pulmicort Respules," said Executive Vice President Paul Hudson.

"AstraZeneca is considering next steps, including an appeal of the court's decision."

The decision comes after AstraZeneca filed infringement lawsuits against Apotex, Watson Laboratories, Breath Limited and Sandoz for infringement of US patents directed to methods of use, formulation and form of active ingredient budesonide for Pulmicort Respules.

At the trial, the company said that the defendants' generic budesonide inhalation suspension products would infringe the claims of the two AstraZeneca patents.

The defendants denied the claims and asserted that each patent was invalid.

The firm stressed that the court's decision was limited to the US and has no impact on the validity of patents elsewhere.

It will also have no effect on the group's revenue guidance for 2013 which is for a mid to high-single digit decline in revenue on a constant currency basis, AstraZeneca insisted.

However, if additional generics enter the market it would materially impact royalties received on sales of Pulmicort Respules.

Royalties represented an annualised value of approximately $260m in 2012 under the core other income line in the company's annual report.

Subject to additional generics entering the market, guidance for core other income in 2013 is estimated to be significantly below $600m. The company expects core earnings per share to fall more than revenue in 2013.

RD

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020

Most Popular

Forget austerity – governments and central banks have no intention of cutting back
Global Economy

Forget austerity – governments and central banks have no intention of cutting back

Once the pandemic is over will we return to an era of austerity to pay for all the stimulus? Not likely, says John Stepek. The money will continue to …
15 Jan 2021
The MoneyWeek Podcast: bitcoin special
Bitcoin

The MoneyWeek Podcast: bitcoin special

Merryn talks to bitcoin experts Dominic Frisby and Charlie Morris to get the lowdown on the cryptocurrency to find out why it's such a huge global phe…
15 Jan 2021
A simple way to profit from the next big trend change in the markets
Investment strategy

A simple way to profit from the next big trend change in the markets

Change is coming to the markets as the tech-stock bull market of the 2010s is replaced by a new cycle of rising commodity prices. John Stepek explains…
14 Jan 2021
Free 6 issue trial then continue to